Skip to main content
OpenTrials
Completed

NCT Number: NCT02110134

A Study of the RevLite Laser System for the Treatment of Refractory Mixed Type Melasma

The purpose of this study is to compare a hydroquinone skin care regimen alone to a combination of Revlite Laser treatment with a hydroquinone skin care regimen for the treatment of melasma.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

NY Laser and Skin Care

New York, 10028, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects with Fitzpatrick Skin Type III-VI
  • Subjects with mixed (epidermal and dermal) type melasma diagnosed by Wood's Lamp.
  • Subjects who are over the age of 18 years of age
  • The subject is willing and able to comply with study instructions and return to the clinic for required visits.
  • The subject's melasma has persisted for greater than 6 months

Exclusion criteria

  • The subject is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period.
  • The subject has a history of cutaneous photosensitization, porphyria, and hypersensitivity to porphyrins or photodermatosis.
  • The subject has any skin pathology or condition that could interfere with the evaluation or requires the use of interfering topical or systemic therapy.
  • The subject has an uncorrected coagulation defect or is currently using anti-coagulation medication (including but not limited to heavy aspirin therapy).
  • The subject has any condition which, in the investigator's opinion, would make it unsafe for the subject to participate in this research study.
  • The subject is currently enrolled in an investigational drug or device trial, or has received an investigational drug or been treated with an investigational device within 30 days prior to entering this study.
  • The subject has used photosensitizing drugs (e.g., Declomycin, sulfa antibiotics, phenothiazines, etc.) within a timeframe where photosensitization from these drugs may still be present.
  • The subject has the need to be exposed to artificial tanning devices or excessive sunlight during the trial.
  • The subject has had prior treatment with parenteral gold therapy (gold sodium thiomalate).
  • The subject has Diabetes Type 1 or 2.
  • The subject has a sensitivity to hydroquinone or Retin-A.
  • The subject has evidence of a compromised immune system or hepatitis.
  • Has had microdermabrasion in past 3 months, other laser or Intense Pulsed Light treatment or chemical peels to the face in past 6 months, injectable fillers, topical retinoids, over-the-counter anti-aging products past 2 weeks.
  • Has a history of keloids or hypertrophic scarring
  • Has permanent make-up and/or is unwilling to refrain from using semi-permanent cosmetics during study

Treatment and study plan

Revlite Laser System with hydroquinone skin care regimen

Device

Revlite Laser System with hydroquinone skin care regimen for the Treatment of Melasma

Hydroquinone skin care regimen

Other

Hydroquinone skin care regimen for the Treatment of Melasma

Primary outcomes

  1. Rates of Adverse Events Among Patients

    Time frame: From study baseline to completion, approximately 1 year. However, adverse events not resolved by then will be followed up with until they are resolved.

    Adverse events were collected and reported to test the safety and efficacy of the device.

Secondary outcomes

  1. Satisfaction Questionnaire

    Time frame: 1 month post last treatment

    Physician and subject satisfaction will be ranked on a scale from 1 to 5, where 1 is extremely dissatisfied and 6 is extremely satisfied.

  2. Photographic Evaluation using the Global Aesthetic Improvement Scale

    Time frame: 1 month post last treatment

    Photos will be a taken at baseline and post treatment and then improvement assessed using the Global Aesthetic Improvement Scale. This scale ranges from 0 to 3, where 0 is 0-25% clearance from baseline photograph, 1 is 25-50% clearance from baseline photograph, 2 is 50-75% clearance from baseline photograph, and 3 is 75-100% clearance from baseline photograph.

Sponsors and collaborators

Lead sponsor

Cynosure, Inc.

Industry

Registry information

Important dates

Study start
2013
Primary completion
2014
Study completion
2014
First posted
Apr 10, 2014
Registry last updated
Nov 17, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.